Chemotherapy regimens with immunotherapy in advanced gastric cancer: A prognostic study using Cox modeling

doi:10.4251/wjgo.121765

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 9

This Article

(11)

(9)

(0)

(114)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Sep 15, 2026; 18(9): 121765
Published online Sep 15, 2026. doi: 10.4251/wjgo.121765

Table 1 Basic patient characteristics and short-term efficacy, n (%)

Characteristic	Overall (n = 298)	PSOX (n = 150)	FOLFOX (n = 42)	SOX + XDL (n = 106)	Statistic	P value
Age					χ² = 0.48	0.788
≤ 60	163 (54.7)	84 (56.0)	21 (50.0)	58 (54.7)
> 60	135 (45.3)	66 (44.0)	21 (50.0)	48 (45.3)
Sex					χ² = 3.25	0.197
Male	235 (78.9)	121 (80.7)	36 (85.7)	78 (73.6)
Female	63 (21.1)	29 (19.3)	6 (14.3)	28 (26.4)
ASA					χ² = 1.07	0.587
1 + 2	259 (86.9)	128 (85.3)	36 (85.7)	95 (89.6)
3	39 (13.1)	22 (14.7)	6 (14.3)	11 (10.4)
Differentiation					χ² = 1.31	0.860
Well	128 (43.0)	65 (43.3)	16 (38.1)	47 (44.3)
Moderate	87 (29.2)	44 (29.3)	15 (35.7)	28 (26.4)
Poorly	83 (27.9)	41 (27.3)	11 (26.2)	31 (29.2)
cT stage					χ² = 4.58	0.333
2	154 (51.7)	75 (50.0)	21 (50.0)	58 (54.7)
3	73 (24.5)	44 (29.3)	9 (21.4)	20 (18.9)
4	71 (23.8)	31 (20.7)	12 (28.6)	28 (26.4)
cN stage					χ² = 0.04	0.979
Positive	210 (70.5)	106 (70.7)	30 (71.4)	74 (69.8)
Negative	88 (29.5)	44 (29.3)	12 (28.6)	32 (30.2)
cTNM
IIB	152 (51.0)	67 (44.7)	25 (59.5)	60 (56.6)
IIIA	52 (17.4)	35 (23.3)	7 (16.7)	10 (9.4)
IIIB	64 (21.5)	29 (19.3)	7 (16.7)	28 (26.4)
IIIC	30 (10.1)	19 (12.7)	3 (7.1)	8 (7.5)
RECIST1.1					χ² = 3.73	0.155
Effective	183 (61.4)	91 (60.7)	21 (50.0)	71 (67.0)
Ineffective	115 (38.6)	59 (39.3)	21 (50.0)	35 (33.0)
Lauren					χ² = 3.47	0.483
Diffuse	101 (33.9)	54 (36.0)	12 (28.6)	35 (33.0)
Mixed	142 (47.7)	65 (43.3)	21 (50.0)	56 (52.8)
Intestinal	55 (18.5)	31 (20.7)	9 (21.4)	15 (14.2)
Location					χ² = 0.83	0.934
Upper	69 (23.2)	32 (21.3)	10 (23.8)	27 (25.5)
Middle	120 (40.3)	61 (40.7)	18 (42.9)	41 (38.7)
Lower	109 (36.6)	57 (38.0)	14 (33.3)	38 (35.8)
TRG					χ² = 6.08	0.048
Effective	226 (75.8)	108 (72.0)	29 (69.0)	89 (84.0)
Ineffective	72 (24.2)	42 (28.0)	13 (31.0)	17 (16.0)
Tumor diameter					χ² = 6.11	0.191
≤ 2	115 (38.6)	59 (39.3)	11 (26.2)	45 (42.5)
2-5	60 (20.1)	34 (22.7)	7 (16.7)	19 (17.9)
≥ 5	123 (41.3)	57 (38.0)	24 (57.1)	42 (39.6)

χ² test: Tumor location is classified as upper 1/3, middle 1/3, lower 1/3, diffuse TNM staging according to the American Joint Committee on Cancer. ASA: American Society of Anesthesiologists Score; FOLFOX: Oxaliplatin plus leucovorin and fluorouracil; PSOX: Plus oxaliplatin and S-1; RECIST: Response Evaluation Criteria in Solid Tumors; SOX + XDL: S-1 combined with sintilimab and oxaliplatin; TRG: Tumor regression grade.

Full Size Table

Citation: Jiang SW, Zhang CG, Wang KD, Shang KP, Yu PJ, Wang HL. Chemotherapy regimens with immunotherapy in advanced gastric cancer: A prognostic study using Cox modeling. World J Gastrointest Oncol 2026; 18(9): 121765
URL: https://www.wjgnet.com/1948-5204/full/v18/i9/121765.htm
DOI: https://dx.doi.org/10.4251/wjgo.121765

Jiang SW, Zhang CG, Wang KD, Shang KP, Yu PJ, Wang HL. Chemotherapy regimens with immunotherapy in advanced gastric cancer: A prognostic study using Cox modeling. World J Gastrointest Oncol 2026; 18(9): 121765 [DOI: 10.4251/wjgo.121765]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.